European Federation of Pharmaceutical Industries and Associations
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
EMA celebrates diversity and inclusion in science and healthcare
The EU body underlines its commitment to diverse perspectives in medicines regulation
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications
J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma
The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer
Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM
The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases
Roche’s Itovebi granted EC approval to treat advanced breast cancer patients
Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases
EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1
Neurofibromatosis type 1 affects an estimated 135,000 people in the EU
EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer
The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019
AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer
More than 35,000 people in five major European countries were treated for the disease last year
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval
The rare inherited disease affects more than 109,000 people worldwide